Publications by authors named "Jan A Anderson"
Article Synopsis
- The Mayo-Baylor RIGHT 10K Study focused on using pharmacogenomics to improve drug prescriptions based on genetic information in a large population.
- Researchers sequenced the DNA of over 10,000 participants to identify genetic variations affecting drug responses, and integrated these findings into electronic health records.
- Results showed that 79% of participants had actionable genetic variants affecting their medication, highlighting the need for a proactive approach to personalized medicine in clinical care.
Objective: To assess bleeding and activated partial thromboplastin time (APTT) in relation to body mass index (BMI) in patients prescribed weight-based dosing of intravenous unfractionated heparin (UFH) for cardiac indications without a maximum (dose-capped) initial bolus or capped initial infusion rate.
Patients And Methods: Consecutive patients admitted to an academic medical center from February 1, 2002, through November 31, 2003, who were treated with a UFH nomogram consisting of a 60-U/kg intravenous bolus plus an initial continuous intravenous infusion of 12 U/kg hourly and titrated to a goal APTT range corresponding to thromboplastin-adjusted target heparin levels of 0.3 to 0.